{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:44Z","timestamp":1791357524504,"version":"4.3.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,1,11]],"date-time":"2015-01-11T00:00:00Z","timestamp":1420934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00213-014-3839-0","type":"journal-article","created":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T19:19:25Z","timestamp":1420831165000},"page":"2061-2070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD"],"prefix":"10.1007","volume":"232","author":[{"given":"Atul R.","family":"Mahableshwarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Serenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,11]]},"reference":[{"key":"3839_CR1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","volume":"15","author":"E Alvarez","year":"2012","unstructured":"Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15:589\u2013600","journal-title":"Int J Neuropsychopharmacol"},{"key":"3839_CR2","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1185\/03007995.2012.725035","volume":"28","author":"DS Baldwin","year":"2012","unstructured":"Baldwin DS, Hansen T, Florea I (2012a) Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 28:1717\u20131724","journal-title":"Curr Med Res Opin"},{"key":"3839_CR3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","volume":"22","author":"DS Baldwin","year":"2012","unstructured":"Baldwin DS, Loft H, Dragheim M (2012b) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 22:482\u2013491","journal-title":"Eur Neuropsychopharmacol"},{"key":"3839_CR4","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, J\u00f8rgensen M, Smith G, Frederiksen K, Jensen KG, Zhnog H, Nielsen SM, Hogg S, M\u00f8rk A, Stensb\u00f8l TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206\u20133221","journal-title":"J Med Chem"},{"key":"3839_CR5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","volume":"26","author":"JP Boulenger","year":"2012","unstructured":"Boulenger JP, Loft H, Florea I (2012) A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 26:1408\u20131416","journal-title":"J Psychopharmacol"},{"key":"3839_CR6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","volume":"29","author":"JP Boulenger","year":"2014","unstructured":"Boulenger JP, Loft H, Olsen CK (2014) Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20\u00a0mg\/day: a randomised, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psyhcopharmacol 29:138\u2013149","journal-title":"Int Clin Psyhcopharmacol"},{"key":"3839_CR7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","volume":"166","author":"JA Bridge","year":"2009","unstructured":"Bridge JA, Birmaher B, Iyengar S, Barbe RP et al (2009) Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatr 166:42\u201349","journal-title":"Am J Psychiatr"},{"key":"3839_CR8","doi-asserted-by":"crossref","first-page":"e4824","DOI":"10.1371\/journal.pone.0004824","volume":"4","author":"AR Brunoni","year":"2009","unstructured":"Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F (2009) Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 4:e4824","journal-title":"PLoS One"},{"key":"3839_CR9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v66n0603","volume":"66","author":"PL Delgado","year":"2005","unstructured":"Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Watkin JG, Detke MJ (2005) Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatr 66:686\u2013692","journal-title":"J Clin Psychiatr"},{"key":"3839_CR10","unstructured":"Guy W (1976) Clinical global impressions (028-CGI). Revised ed. Rockville, MD: U.S. Dept. of\u00a0Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 217\u2013222."},{"key":"3839_CR11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355","journal-title":"Br J Med Psychol"},{"key":"3839_CR12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","volume":"73","author":"N Henigsberg","year":"2012","unstructured":"Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME (2012) A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatr 73:953\u2013959","journal-title":"J Clin Psychiatr"},{"key":"3839_CR13","unstructured":"Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi M (2013) A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10\u00a0mg and 20\u00a0mg in adults with major depressive disorder [abstract]. American Psychiatric Association (APA) 166th Annual Meeting 2013 (manuscript submitted for publication J Clin Psych)"},{"key":"3839_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","volume":"16","author":"R Jain","year":"2013","unstructured":"Jain R, Mahableshwarkar A, Jacobson P, Chen Y, Thase ME (2013) A randomized, double-blind, placebo-controlled 6-weeks trial of the efficacy and tolerability of 5\u00a0mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 16:313\u2013321","journal-title":"Int J Neuropsychopharmacol"},{"key":"3839_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","volume":"27","author":"C Katona","year":"2012","unstructured":"Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215\u2013223","journal-title":"Int Clin Psychopharmacol"},{"key":"3839_CR16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5949.2010.00151.x","volume":"16","author":"A Khan","year":"2010","unstructured":"Khan A, Bhat A, Kolts R, Thase ME et al (2010) Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 16:217\u2013226","journal-title":"CNS Neurosci Ther"},{"key":"3839_CR17","unstructured":"Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi M (2013a) A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients [abstract]. American Psychiatric Association (APA) 166th Annual Meeting 2013 (manuscript submitted for publication J Clin Psych)"},{"key":"3839_CR18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","volume":"29","author":"AR Mahableshwarkar","year":"2013","unstructured":"Mahableshwarkar AR, Jacobsen PL, Chen Y (2013b) A randomized, double-blind trial of 2.5\u00a0mg and 5\u00a0mg vortioxetine (Lu AA21004) versus placebo for 8\u00a0weeks in adults with major depressive disorder. Curr Med Res Opin 29:217\u2013226","journal-title":"Curr Med Res Opin"},{"key":"3839_CR19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","volume":"26","author":"CA McGahuey","year":"2000","unstructured":"McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnoght KM, Manber R (2000) The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26:25\u201340","journal-title":"J Sex Marital Ther"},{"key":"3839_CR20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134:382\u2013389","journal-title":"Br J Psychiatr"},{"key":"3839_CR21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","volume":"340","author":"A M\u00f8rk","year":"2012","unstructured":"M\u00f8rk A, Pehrson A, Brennum L, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensb\u00f8l TB (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340:666\u2013675","journal-title":"J Pharmacol Exp Ther"},{"key":"3839_CR22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JCP.0b013e3180387820","volume":"27","author":"JC Mundt","year":"2007","unstructured":"Mundt JC, Greist JH, Jefferson JW, Katzelnick DJ et al (2007) Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol 27:121\u2013125","journal-title":"J Clin Psychopharmacol"},{"key":"3839_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","volume":"23","author":"AL Pehrson","year":"2013","unstructured":"Pehrson AL, Cremers T, Betry C, van der Hart MG, J\u00f8rgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C (2013) Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters\u2014a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 23:133\u2013145","journal-title":"Eur Neuropsychopharmacol"},{"key":"3839_CR24","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oguendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatr 168:1266\u20131277","journal-title":"Am J Psychiatr"},{"key":"3839_CR25","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatr 163:1905\u20131917","journal-title":"Am J Psychiatr"},{"key":"3839_CR26","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Asin K, Artigas F (2014) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. doi: 10.1016\/j.pharmthera.2014.07.001","journal-title":"Pharmacol Ther"},{"key":"3839_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","volume":"29","author":"A Serretti","year":"2009","unstructured":"Serretti A, Chiesa A (2009) Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29:259\u2013266","journal-title":"J Clin Psychopharmacol"},{"key":"3839_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","volume":"11","author":"DV Sheehan","year":"1996","unstructured":"Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. Int Clin Psychopharmacol 11:89\u201395","journal-title":"Int Clin Psychopharmacol"},{"key":"3839_CR29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatr 163:28\u201340","journal-title":"Am J Psychiatr"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3839-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3839-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T14:12:33Z","timestamp":1551190353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3839-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,11]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3839-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,11]]}}}